尿液标志物在神经变性和脱髓鞘性疾病中的研究进展  

Research progress of urinary biomarkers in both neurodegenerative and demyelinating diseases

作　　者：张月琪 任汝静[1] 王刚[1] 

机构地区：[1]上海交通大学医学院附属瑞金医院神经内科上海交通大学医学院神经病研究所,上海200025

出　　处：《重庆医科大学学报》2017年第6期749-754,共6页Journal of Chongqing Medical University

基　　金：国家自然科学基金面上资助项目(编号:81171027);上海交通大学医学院转化医学协同创新中心合作研究资助项目(编号:2015272)

摘　　要：近年来,基于尿液代谢组学等方法的生物标志物因其高灵敏度、高通量和高稳定性等优点已经在多种神经变性病和神经脱髓鞘性疾病的早期诊断和机制探索中得到应用,虽然目前大部分尿液标志物的作用机制尚不明确,但神经变性病尿液标志物中,氧化应激导致氨基酸、脂质和DNA等细胞成分过氧化的代谢产物占据了主要地位,而神经脱髓鞘疾病中,主要来自各种免疫相关成分。合格的标志物不仅可以反映疾病病理生理变化,还有助于在出现明显的临床表现前对患者进行早期诊断与治疗。With the advantages of high sensitivity,throughput and reliability,urinary metabolomics has been widely applied in both neurodegenerative and demyelinating diseases for early diagnosis and pathogenesis exploration in recent years. Although,the mechanism of most urinary biomarkers is not clearly confirmed at present. Numerous studies have suggested that the products of DNA,lipid and protein oxidation play major roles in urinary biomarkers of neurodegenerative diseases,while the primary components in demyelinating diseases are substances associated with inflammation. Generally,a qualified biomarker not only reflects pathophysiological processes,but also contributes to early diagnosis and treatment before obvious symptoms start.

关 键 词：神经变性病 神经脱髓鞘疾病 尿液标志物 

分 类 号：R749.15[医药卫生—神经病学与精神病学]